Clinical Trial Update: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 gene therapy trial for APOE4 homozygous Alzheimer's disease by Lexeo Therapeutics; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Early-onset Alzheimer Disease

Drugs mentioned

• APOE4-targeted gene therapy

Snippet

Sponsor: Lexeo Therapeutics | Conditions: Alzheimer Disease, Early Onset Alzheimer Disease | Phase 1, Phase 2 | Status: COMPLETED